The landscape of reconstructive and aesthetic surgery is poised for a significant transformation as the American Society of Plastic Surgeons (ASPS) and MedTech Innovator (MTI) announce the latest cohort of startups selected for their prestigious Plastic Surgery specialty track. Five trailblazing companies—FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist—have emerged from a pool of 135 applicants to join the 2026 MedTech Innovator accelerator, a program renowned for turning nascent medical concepts into clinical realities.
This partnership, now entering its fifth year, serves as a bridge between the operating room and the boardroom, ensuring that the next generation of medical devices, diagnostic tools, and digital health platforms are not only technologically advanced but fundamentally aligned with the complex, nuanced needs of plastic surgery patients.
A Rigorous Path to Selection
The selection process for the 2026 track was characterized by unprecedented interest. With 135 startups vying for a spot, the selection committee—comprised of industry veterans, venture capitalists, and leading plastic surgeons—faced the daunting task of filtering candidates based on clinical utility, scalability, and the potential to disrupt current standards of care.
Following an exhaustive review of technical dossiers and business models, 12 finalists were invited to San Francisco for a live-pitch event. This high-stakes environment tested the founders’ ability to articulate the value of their technologies under the scrutiny of experts. The final five, chosen for their distinct approaches to tissue engineering, diagnostic imaging, and artificial intelligence, will now embark on an intensive accelerator journey.
"Plastic surgery has always been a specialty driven by innovation," noted Babak Mehrara, MD, president of The Plastic Surgery Foundation. "The Society’s unique partnership with MedTech Innovator allows us to help shape the next generation of technologies. By connecting entrepreneurs with the expertise of plastic surgeons, we’re helping ensure these solutions are developed with patients’ needs in mind while accelerating innovations that have the potential to strengthen patient care across the specialty."
The 2026 Cohort: Who They Are
The selected startups represent a cross-section of modern medical advancement:
- FeminAI: Leveraging artificial intelligence to personalize diagnostic and procedural outcomes for female patients, focusing on precision medicine in aesthetic and reconstructive procedures.
- ImageAssist: A digital health startup aiming to streamline preoperative planning and intraoperative visualization through advanced imaging and augmented reality.
- GenesisTissue: A biotechnology venture focusing on the future of regenerative medicine, exploring new frontiers in synthetic and biological scaffolding for tissue reconstruction.
- Tissuelock: A surgical device company dedicated to improving wound closure and tissue stability, addressing critical challenges in recovery and scar mitigation.
- GenAssist: A diagnostic-focused company utilizing genetic data to predict patient outcomes and optimize personalized surgical interventions.
These five companies will now join a larger cohort of 65 startups, all of whom are competing for a portion of $800,000 in non-dilutive funding. The winners of the competition will be unveiled this fall during The MedTech Conference in Boston.
Chronology of the ASPS-MTI Partnership
The collaboration between ASPS and MedTech Innovator is not a new experiment but a proven model for success. Since its inception in 2022, the partnership has systematically identified and cultivated technologies that solve some of the most persistent problems in the operating room.
Year 1–2: Establishing the Pipeline
The early years of the partnership focused on proof-of-concept. By embedding the ASPS specialty track into the broader MTI framework, the Society ensured that plastic surgeons were involved in the development cycle of devices from day one. This era saw early startups gaining exposure to regulatory pathways and hospital procurement models.
Year 3–4: Scaling and Impact
As the program matured, the focus shifted toward commercialization. With 18 companies having passed through the program to date, the track has demonstrated significant economic impact. These 18 startups have raised a collective $120 million in venture funding, underscoring the investor confidence in the plastic surgery technology sector.
Year 5: The 2026 Expansion
The current year marks a maturation of the process. With 135 applicants, the program is no longer just "finding" startups; it is curating a pipeline that reflects the top tier of global medtech talent. The inclusion of these five companies signals a shift toward AI-integrated care and tissue regeneration, two of the most rapidly evolving fields in medicine.
Supporting Data: Why This Matters
The success of the ASPS-MTI accelerator is rooted in a data-driven approach to innovation. MedTech Innovator, founded in 2013, is the world’s largest accelerator of its kind. Its track record is formidable:
- 800+ Startups Supported: The program has provided a launchpad for hundreds of companies, many of which have gone on to become industry leaders.
- $11 Billion in Equity Funding: The collective capital raised by MTI alumni reflects the massive market demand for transformative healthcare technologies.
- 500+ FDA Approvals: The program is a primary catalyst for moving products through the complex regulatory hurdles of the FDA, a critical metric for any medtech startup.
- ASPS Specific Metrics: The 18 companies that have participated in the plastic surgery track have already secured more than $337,000 in prizes and seen two successful corporate exits, proving that the niche focus of the specialty track produces high-value outcomes.
Clinical Implications: Improving Patient Outcomes
The ultimate goal of this initiative is to move beyond the excitement of "new technology" and address the tangible realities of patient care. In plastic and reconstructive surgery, where outcomes are often measured by functional restoration, aesthetics, and patient satisfaction, the technologies being developed carry significant weight.
"By providing these companies with mentorship from senior industry executives and feedback from surgeons, we ensure that they aren’t just creating a product—they are solving a problem," says an ASPS spokesperson.
For instance, companies like Tissuelock and GenesisTissue are working to resolve the age-old challenges of wound dehiscence and tissue necrosis. If successful, these technologies could significantly reduce hospital readmission rates, shorten recovery times, and improve long-term functional outcomes for patients undergoing complex reconstructive surgeries, such as those following cancer treatment or trauma.
Engagement and Future Outlook
The accelerator program is structured to provide continuous support. Beyond the initial selection, participants undergo a rigorous coaching program. They are paired with mentors—senior executives from major medical device companies—who provide individualized guidance on everything from intellectual property strategy to clinical trial design.
The next major milestone for the 2026 cohort will be their participation at Plastic Surgery The Meeting, scheduled for October 15–18 in Houston. This event provides the startups with a unique platform to showcase their technologies to thousands of plastic surgeons. For the surgeons, it is a preview of the tools that may soon be in their hands; for the startups, it is a crucial opportunity to gain user feedback, form partnerships, and demonstrate real-world utility to the very people who will ultimately integrate these tools into their practices.
About the Catalyst: MedTech Innovator
MedTech Innovator’s position as the world’s premier nonprofit startup accelerator is defined by its collaborative model. Based in Los Angeles, the organization acts as a neutral convener, bringing together 35 corporate partners—including the world’s largest medical device manufacturers—with early-stage innovators.
Its mission is simple: to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. By providing a low-friction environment for startups to gain mentorship, funding, and industry networking, MedTech Innovator has become the gold standard for navigating the "valley of death" that often kills promising medical startups.
As the 2026 cohort prepares for the next phase of the program, the expectations are high. The partnership between ASPS and MedTech Innovator continues to prove that when clinical expertise meets business acceleration, the result is not just a stronger bottom line, but a more resilient and capable healthcare system for patients worldwide.
For those tracking the future of surgery, the developments in Boston this fall will be critical. The intersection of artificial intelligence, biotechnology, and surgical precision is here, and through programs like this, it is being refined, tested, and brought to the bedside.
About the Author
